Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016
July 24, 2016 09:30 ET
|
Anavex Life Sciences Corp.
Results Feature Favorable Safety, Maximum Tolerated Dose, Positive Dose Response as well as Positive Unexpected Therapeutic Response Events NEW YORK, July 24, 2016 (GLOBE NEWSWIRE) -- Anavex Life...
Anavex to Present at the Alzheimer’s Association International Conference (AAIC) 2016
July 12, 2016 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, July 12, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex to Present at the 2016 Rett Syndrome Symposium
June 23, 2016 16:50 ET
|
Anavex Life Sciences Corp.
NEW YORK, June 23, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
June 22, 2016 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, June 22, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X – Autism-Related Disorders
June 06, 2016 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, June 06, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated...
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
May 20, 2016 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, May 20, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
May 18, 2016 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, May 18, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Reports Fiscal Second Quarter 2016 Financial Results
May 11, 2016 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, May 11, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
April 08, 2016 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, April 08, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated...
Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
March 14, 2016 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, March 14, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...